IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $55.45 Average Price Target from Brokerages

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have earned an average recommendation of "Buy" from the fifteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Fourteen analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $55.45.

Several analysts have recently commented on the company. JPMorgan Chase & Co. decreased their target price on IDEAYA Biosciences from $69.00 to $66.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. Oppenheimer lowered their target price on IDEAYA Biosciences from $60.00 to $53.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 7th. Mizuho started coverage on shares of IDEAYA Biosciences in a research report on Monday, July 8th. They issued an "outperform" rating and a $50.00 price target for the company. Cantor Fitzgerald began coverage on shares of IDEAYA Biosciences in a research report on Tuesday, October 15th. They set an "overweight" rating on the stock. Finally, BTIG Research increased their target price on shares of IDEAYA Biosciences from $55.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, July 9th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP acquired a new position in IDEAYA Biosciences in the 4th quarter valued at $2,988,000. Vanguard Group Inc. boosted its holdings in IDEAYA Biosciences by 17.0% during the fourth quarter. Vanguard Group Inc. now owns 3,475,772 shares of the company's stock valued at $123,668,000 after acquiring an additional 504,275 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of IDEAYA Biosciences in the first quarter valued at about $67,000. Principal Financial Group Inc. increased its stake in shares of IDEAYA Biosciences by 4.4% in the first quarter. Principal Financial Group Inc. now owns 15,275 shares of the company's stock worth $670,000 after purchasing an additional 648 shares during the period. Finally, Capstone Investment Advisors LLC lifted its position in shares of IDEAYA Biosciences by 7.1% during the 1st quarter. Capstone Investment Advisors LLC now owns 59,180 shares of the company's stock worth $2,597,000 after purchasing an additional 3,941 shares during the last quarter. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Price Performance

NASDAQ IDYA traded up $0.10 on Friday, hitting $29.30. 1,014,240 shares of the company were exchanged, compared to its average volume of 807,308. IDEAYA Biosciences has a twelve month low of $25.22 and a twelve month high of $47.74. The company's 50 day moving average price is $34.15 and its 200-day moving average price is $37.38. The firm has a market capitalization of $2.48 billion, a P/E ratio of -13.38 and a beta of 0.82.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.14). During the same quarter last year, the firm posted ($0.50) EPS. As a group, equities analysts expect that IDEAYA Biosciences will post -2.48 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.